Humacyte, Inc. cotiza a 0.37 USD y tiene una capitalización bursátil de $102M. En los últimos 12 meses ha facturado $2M con un margen de flujo de caja libre del -5197.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific tech…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.16 | $-0.09 | $-0.13 |
| Estimado | $-0.08 | $-0.10 | $-0.11 | $-0.13 |
| Sorpresa | — | -60.0% | +18.2% | +0.0% |
| Métrica | HUMA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | -376.1% | 57.0% | -433.1% |
| Operating Margin | -5306.0% | -38.6% | -5267.4% |
| Net Margin | -2003.6% | -33.6% | -1970.0% |
| FCF Margin | -5197.6% | -13.9% | -5183.7% |
| ROE | -1313.4% | -40.4% | -1273.0% |
| ROA | -35.1% | -32.0% | -3.1% |
| Current Ratio | 3.69 | 2.84 | +0.85 |
| Debt / Equity | 11.40 | 0.28 | +11.12 |